Glutaminases (GLS1 and GLS2) are mitochondrial phosphate-activated amidohydrolase enzymes that catalyze the irreversible deamination of Glutamine to glutamate and ammonia. They serve as the rate-limiting step in glutaminolysis, a metabolic pathway essential for proliferating cells including activated leukocytes, Cancer cells, and enterocytes. The two isoforms have distinct regulatory mechanisms: GLS1 is oncogene-driven (c-Myc, Rho GTPases), while GLS2 is tumor suppressor-linked (p53).
Think of glutaminase as a specialist disassembly worker in a metabolic factory where Glutamine arrives as a two-compartment shipping container. Glutaminase is the forklift operator who splits each container into two parts: one becomes glutamate (which gets further processed into α-ketoglutarate for the TCA cycle power plant), and the other releases ammonia (nitrogen) that's shipped to the biosynthesis department for building nucleotides and amino acids. The factory has two different forklift models: GLS1 works in the rapid-growth wing (activated when the factory boss c-Myc demands maximum output for cell division), while GLS2 operates in the quality-control section (supervised by p53, the factory inspector). When Cancer cells hijack the factory, they crank up the GLS1 forklifts to maximum speed, becoming so dependent on this Glutamine unloading that if you jam the forklifts (with GLS1 inhibitors), the cancer factory grinds to a halt. Meanwhile, immune cells doing battle also call in extra GLS1 forklifts to fuel their attack—they're literally burning Glutamine containers as fast as they arrive to power their weapons systems.
Activation cascade:
- c-Myc oncogene → binds E-box elements in GLS1 promoter → transcriptional upregulation
- Rho GTPases → activate GLS1 via conformational change → enhanced enzymatic activity
- mTORC1 signaling → increases GLS1 translation → elevated protein levels
Enzymatic reaction:
Glutamine + H₂O → Glutamate + NH₃ (ΔG = -14 kJ/mol)
Downstream cascade:
- Glutamate → glutamate dehydrogenase (GDH) → α-ketoglutarate + NADH + NH₃
- α-ketoglutarate → enters TCA Cycle → provides anaplerotic carbon source
- α-ketoglutarate → substrate for 2-Oxoglutarate-dependent dioxygenases → regulates HIF degradation via PHD enzymes
- α-ketoglutarate → substrate for histone demethylases (KDM family) → Epigenetic Modifications
- NH₃ → carbamoyl phosphate synthetase → nucleotide biosynthesis
- NH₃ → Glutamine synthetase → glutamine-glutamate cycling
Activation cascade:
- p53 tumor suppressor → binds response elements in GLS2 promoter → transcriptional activation
- Oxidative Stress → p53 activation → GLS2 upregulation → glutamate production
- Glutamate → ↑ Glutathione synthesis → antioxidant defense
Metabolic partitioning:
GLS2-derived glutamate preferentially fuels Glutathione synthesis rather than TCA Cycle anaplerosis, creating functional distinction from GLS1.
graph TD
A[Glutamine] --> B{Glutaminase}
B -->|GLS1 c-Myc| C[Glutamate rapid]
B -->|GLS2 p53| D[Glutamate controlled]
C --> E["α-ketoglutarate"]
D --> F[Glutathione synthesis]
E --> G[TCA Cycle]
E --> H[Epigenetic regulation]
E --> I[HIF regulation]
C --> J["NH₃ biosynthesis"]
G --> K["ATP + NADH"]
J --> L[Nucleotides]
J --> M[Amino acids]
F --> N[Antioxidant defense]
style B fill:#ff9999
style E fill:#99ccff
style K fill:#99ff99
¶ Cellular Localization and Regulation
- GLS1: Inner mitochondrial membrane, activated by inorganic phosphate (Pi), inhibited by glutamate (product inhibition, IC₅₀ ~10 mM)
- GLS2: Mitochondrial matrix, less sensitive to glutamate inhibition
- Allosteric activation: Phosphate binding shifts oligomeric state from inactive tetramer → active octamer
- Post-translational modification: S-nitrosylation of GLS1 at Cys-156 → ↓ activity (Nitric Oxide regulation)
- c-Myc amplification → 3-10x GLS1 mRNA increase
- K-Ras mutation → PI3K-AKT pathway → mTORC1 → GLS1 translation
- HIF-1 → indirect GLS1 activation via metabolic reprogramming
- miR-23a/b downregulation → loss of GLS1 translational suppression
Many solid tumors (particularly triple-negative breast cancer, glioblastoma, pancreatic cancer) exhibit "Glutamine addiction"—dependence on glutaminolysis for survival. GLS1 expression correlates with:
- Tumor grade and proliferation index (Ki-67 >30%)
- Resistance to glucose deprivation (Warburg-independent growth)
- Chemotherapy resistance (provides alternative ATP source)
Threshold for clinical relevance: GLS1 overexpression ≥2-fold vs. normal tissue predicts poor prognosis in colorectal and lung cancer.
Intervention implications:
- GLS1 inhibitors (CB-839/Telaglenastat, BPTES) in clinical trials for solid tumors
- Dietary Glutamine restriction shows limited efficacy (gut and immune cells also require Glutamine)
- Combination therapy: GLS1 inhibition + mTORC1 blockade synergistic in preclinical models
¶ Immune Activation and Glutaminolysis
Activated leukocytes switch from Glucose-dominant to Glutamine-dominant metabolism:
- T cell activation (CD3/CD28 stimulation) → c-Myc induction → GLS1 upregulation within 6-12 hours
- Macrophage Polarization to M1 → ↑ GLS1 for citrate production → itaconate synthesis (antimicrobial)
- Neutrophil respiratory burst → consumes Glutamine at 5-10x basal rate
Clinical threshold: Plasma Glutamine drops from 600 μM → 300 μM during sepsis, correlating with immune dysfunction.
Metamodel connections:
¶ Gut Barrier and Enterocyte Function
Enterocytes are the highest Glutamine consumers in the body (40% of arterial Glutamine):
Intervention paradox: Glutamine supplementation (15-30 g/day) improves gut barrier in critical illness but may fuel GLS1-dependent tumors—risk-benefit assessment required.
¶ Neuroinflammation and Excitotoxicity
GLS1-derived glutamate in Microglia contributes to:
Clinical biomarker: CSF glutamate/Glutamine ratio >0.5 indicates active glutaminolysis in CNS inflammation.
GLS1 inhibitors in development:
- CB-839 (Telaglenastat): Phase II trials in renal cell carcinoma, triple-negative breast cancer
- BPTES (preclinical): Selective GLS1 inhibitor, poor bioavailability
- Compound 968: Non-competitive GLS inhibitor, crosses blood-brain barrier
Natural compounds with GLS inhibitory activity:
- Isoforms: GLS1 (kidney-type, KGA splice variant 65 kDa; GAC splice variant 58 kDa) vs. GLS2 (liver-type, 65 kDa)
- Km for glutamine: GLS1 = 2-4 mM; GLS2 = 10-15 mM (GLS1 more efficient at physiological concentrations)
- Tissue distribution: GLS1 highest in kidney, brain, immune cells; GLS2 highest in liver, pancreas, neuronal cells
- Glutamine consumption rate: Proliferating cells consume Glutamine at 0.5-2.0 pmol/cell/hour (comparable to Glucose at 1-5 pmol/cell/hour)
- Cancer dependency threshold: Tumor cells with c-Myc amplification require ≥200 μM Glutamine for viability; normal cells tolerate <50 μM
- Ammonia toxicity: GLS1 overactivity generates NH₃ → urea cycle burden → hyperammonemia risk (>100 μM plasma NH₃)
- Epigenetic role: α-ketoglutarate from glutaminolysis is cofactor for >60 2-Oxoglutarate-dependent enzymes including TET DNA demethylases and Jumonji histone demethylases
- Immune requirement: T cell proliferation requires Glutamine at ≥2 mM; below this threshold, IL-2 production drops 70%
- Redox balance: GLS2-derived glutamate increases Glutathione synthesis 2-3x vs. GLS1 pathway
- Drug resistance: GLS1 inhibition in Cancer cells triggers compensatory upregulation of Glucose transporters (GLUT1, GLUT3) and glycolytic enzymes within 48 hours
- Evolutionary conservation: GLS genes present in all vertebrates; GLS1 duplicated in mammals during brain expansion ~200 million years ago
- Glutamine — glutaminase substrate; plasma levels 500-700 μM determine enzyme saturation and cellular uptake
- glutamate — direct enzymatic product; neurotransmitter, TCA Cycle anaplerotic substrate, Glutathione precursor
- TCA Cycle — α-ketoglutarate from glutamate enters at complex II, bypassing citrate synthase for anaplerosis
- 2-Oxoglutarate — identical to α-ketoglutarate; regulates HIF stability via PHD enzymes and chromatin methylation status
- Cancer — GLS1 upregulation in c-Myc-driven tumors; therapeutic target for glutamine-addicted malignancies
- Immune Activation — T cells, macrophages, neutrophils upregulate GLS1 during activation to fuel proliferation and effector functions
- c-Myc — master transcriptional regulator of GLS1 expression via E-box binding; amplified in 30% of human cancers
- ATP — glutaminolysis generates 30 ATP/glutamine (vs. 36 ATP/glucose) via TCA cycle and Oxidative Stress phosphorylation
- mTORC1 — signaling hub that increases GLS1 translation via 4E-BP1 phosphorylation and S6K activation
- Glucose — metabolic competitor; cells shift between glycolysis and glutaminolysis based on nutrient availability
- enterocytes — highest glutaminase activity per cell in body; consume 40% of arterial Glutamine for barrier maintenance
- leukocytes — activated lymphocytes upregulate GLS1 6-8x within 12 hours of antigen presentation
- HIF-1 — indirectly regulated by glutaminolysis-derived α-ketoglutarate availability for PHD hydroxylases
- Glutathione — GLS2 pathway preferentially supports Glutathione synthesis for Antioxidant defense
- Warburg Effect — glutaminolysis complements aerobic glycolysis in Cancer cells, providing biosynthetic precursors glycolysis cannot
- Epigenetic Modifications — α-ketoglutarate is cofactor for histone demethylases (KDM2-7 families) and DNA demethylases (TET1-3)
- Ammonia — toxic byproduct requiring hepatic urea cycle detoxification; GLS1 overactivity risks hyperammonemia
- Intestinal permeability — Glutamine depletion reduces enterocytes energy → impaired tight junctions → leaky gut
- Sepsis — plasma Glutamine falls 50% during severe sepsis, correlating with immune dysfunction and mortality
- Macrophage Polarization — M1 macrophages use GLS1-derived citrate for itaconate synthesis (antimicrobial metabolite)
- Mitochondrial dysfunction — GLS1 activity depends on intact electron transport chain for NAD⁺ regeneration
- Oxidative Stress — p53 activation by ROS upregulates GLS2 → glutamate → Glutathione synthesis as antioxidant response
- Inflammation — pro-inflammatory cytokines (IL-1, TNF-α) upregulate GLS1 in stromal cells, fueling inflammatory environment
- NADH — glutamate dehydrogenase produces NADH for Electron transport chain, linking glutaminolysis to ATP production
- Autophagy — Glutamine withdrawal triggers Autophagy via AMPK activation; cells recycle proteins to sustain amino acid pools
- Module 5 — Hypoxia and metabolic reprogramming; HIF regulation by α-ketoglutarate availability from glutaminolysis